NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Sionna Therapeutics, Inc. (SION) Stock Analysis

Sionna Therapeutics, Inc. (SION) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SION

$7.18

+$0.43 (+6.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SION with… →

SION Key Statistics

As of Sep 4, 2026
Trading
Open
$6.68
Previous Close
$6.75
Day's Range
6.62–7.22
52-Week Range
4.01–54.97
Volume
921.80K
Valuation
Market Cap
$324.18M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$75.27M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.15M
1-Year Return
−68.86%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.87M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SION Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−82.55%
2025 (partial year)+64.56%

As of September 4, 2026.

SION Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$75.27M—
2024$0.00−$61.69M—
2023$0.00−$47.26M—
2022$0.00−$40.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$88.98M−$75.27M—
2024$0.00—−$70.56M−$61.69M—
2023$0.00—−$50.33M−$47.26M—
2022$0.00—−$41.37M−$40.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SION Valuation vs Biotechnology Median

Median of 656 stocks
MetricSIONBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sionna Therapeutics, Inc. (SION) is capitalised at $324.18M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 59.

SION last closed at $7.18 on September 4, 2026. That is +$0.43 (+6.37%) against the previous close. Over the past 52 weeks the price has ranged from $4.01 to $54.97. The latest close sits 79.05% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $75.27M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −68.86%. The stored price history starts on February 7, 2025, and the total return since then is −71.28%. Daily returns over the trailing 1 year annualize to a volatility of 124.19%.

Growth & Income

No dividend is on file for SION.

So far in 2026 the price is −82.55%.

Peer Comparison

Sionna Therapeutics, Inc. (SION) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sionna Therapeutics, Inc. SION $324.18M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Sionna Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Visit website →